Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor

Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor

In the past decade, fecal microbiota transplantation (FMT) has rapidly spread worldwide in clinical practice as a highly effective treatment option against recurrent <i>Clostridioides difficile</i> infection. Moreover, new evidence also supports a role for FMT in other conditions, such a...

Full description

Bibliographic Details
Main Authors:	Stefano Bibbò, Carlo Romano Settanni, Serena Porcari, Enrico Bocchino, Gianluca Ianiro, Giovanni Cammarota, Antonio Gasbarrini
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Journal of Clinical Medicine
Subjects:	gut microbiota precision medicine <i>Clostridium difficile</i> inflammatory bowel disease ulcerative colitis irritable bowel disease
Online Access:	https://www.mdpi.com/2077-0383/9/6/1757

Similar Items

Risk Factors, Diagnosis, and Management of <i>Clostridioides difficile</i> Infection in Patients with Inflammatory Bowel Disease
by: Livio Enrico Del Vecchio, et al.
Published: (2022-06-01)

Update on fecal microbiota transplantation
by: M. Fiorani, et al.
Published: (2023-10-01)

Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center
by: Gianluca Ianiro, et al.
Published: (2021-01-01)

Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond
by: Thomas J. Borody, et al.
Published: (2015-07-01)

Efficacy of fidaxomicin therapy, after failure of vancomycin therapy, for treating a C. difficile colitis in a patient with ulcerative colitis
by: Carlo Tascini, et al.
Published: (2015-05-01)

Recurrent Multidrug-Resistant <i>Clostridium difficile</i> Infection Secondary to Ulcerative Colitis a Case Report
by: Arturo P. Jaramillo, et al.
Published: (2023-08-01)

C lostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes
by: Rachel Bernard, et al.
Published: (2022-08-01)

Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome
by: Hamid Kalantari, et al.
Published: (2015-01-01)

A Multifaced Aspect of <i>Clostridium difficile</i> Infection in Pediatric Patients with Inflammatory Bowel Disease: Case Series and Literature Review
by: Elena Iana, et al.
Published: (2023-09-01)

The prevalence and clinical characteristics of Clostridium difficile infection in Saudi patients admitted with inflammatory bowel disease: A case–control study
by: Abdulrahman AlKhormi, et al.
Published: (2023-01-01)

The Current Knowledge on <em>Clostridioides</em><em> difficile</em> Infection in Patients with Inflammatory Bowel Diseases
by: Alina Boeriu, et al.
Published: (2022-07-01)

Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease
by: Marta Gravito-Soares, et al.

Role of fecal calprotectin as a biomarker of intestinal inflammation in ulcerative colitis: a prospective study
by: Onişor Danusia, et al.
Published: (2018-07-01)

Clostridium difficile in ulcerative colitis; a retrospective study
by: O. V. Knyazev, et al.
Published: (2018-11-01)

Application and development of fecal microbiota transplantation in the treatment of gastrointestinal and metabolic diseases: A review
by: Hassan Mahmoudi, et al.
Published: (2023-01-01)

Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives
by: Hyun Ho Choi, et al.
Published: (2016-05-01)

Diagnostic Implications of Irritable Bowel Syndrome Is an Independent Risk Factor for Undergoing Surgical Interventions in Patients with Inflammatory Bowel Disease
by: Yuhan Fu, et al.
Published: (2023-05-01)

Current applications of fecal microbiota transplantation in intestinal disorders
by: Wen‐Hung Hsu, et al.
Published: (2019-06-01)

Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome
by: Porter Chad K, et al.
Published: (2012-05-01)

Are Probiotics or Prebiotics useful in pediatric irritable bowel syndrome or inflammatory bowel disease?
by: Stefano eGuandalini
Published: (2014-08-01)

Features of the mucous barrier in functional bowel diseases and ulcerative colitis
by: A.E. Dorofeyev, et al.
Published: (2022-06-01)

The cardiovascular system in patients with functional and inflammatory bowel diseases
by: I V Maev, et al.
Published: (2018-02-01)

Value of fecal calprotectin in the diagnosis of chronic inflammatory bowel diseases in children
by: T.V. Yaroshevska, et al.
Published: (2018-03-01)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
by: Abdulaziz Saad Alshahrani, et al.
Published: (2023-09-01)

Telocytes’ Role in Modulating Gut Motility Function and Development: Medical Hypotheses and Literature Review
by: Daniel Dumitru Banciu, et al.
Published: (2022-06-01)

Clostridioides Infection in Patients with Inflammatory Bowel Disease
by: Mi Rae Lee, et al.
Published: (2022-08-01)

Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease
by: Azimirad M, et al.
Published: (2020-09-01)

Evaluation of the diagnostic performance of estimated fecal calprotectin and serum intelectin-1 and C-reactive protein solo or in combination for differentiation between patients with query ulcerative colitis and irritable bowel syndrome
by: Rizk Sayad R. Sarhan, et al.
Published: (2023-11-01)

Fecal Calprotectin in Inflammatory Bowel Disease
by: Jun Lee
Published: (2016-05-01)

<it>Blastocystosis</it> in patients with gastrointestinal symptoms: a case–control study
by: Cekin Ayhan, et al.
Published: (2012-09-01)

Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis
by: Jessica Emily Green, et al.
Published: (2020-11-01)

Clostridium difficile infection in a patient with Crohn disease
by: Chien-Hui Hsu, et al.
Published: (2012-06-01)

(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review
by: Marilyn Hagan, et al.
Published: (2021-03-01)

Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study
by: Dorte Melgaard, et al.
Published: (2022-03-01)

Fecal calprotectin in inflammatory bowel disease
by: Walsham NE, et al.
Published: (2016-01-01)

Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease
by: Sahil Khanna, et al.
Published: (2017-05-01)

The role of fecal calprotectin in investigating inflammatory bowel diseases
by: Mustafa Erbayrak, et al.
Published: (2009-05-01)

Irritable Bowel Syndrome Is an Independent Risk Factor for Developing Opioid Use Disorder in Patients with Inflammatory Bowel Disease
by: Yuhan Fu, et al.
Published: (2023-05-01)

New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance
by: Kartikeya Tripathi, et al.
Published: (2019-04-01)

Ulcerative colitis: Al-gassim experience
by: Contractor Qais, et al.
Published: (2004-01-01)